Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Inhibrx Biosciences, Inc
Toray Industries, Inc
Shanghai Junshi Bioscience Co., Ltd.
Eli Lilly and Company
Nektar Therapeutics
City of Hope Medical Center
Mayo Clinic